CTYPE html> ProCanBio | Biomarker Card

Biomarker Card

This biomarker card gives comprehensive information about each biomarker.
Detailed Information
Biomarker ID474
PMID19652763
Year2009
BiomarkerCCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa)
Biomarker BasisExpression Based
BiomoleculemRNA
SourceTissue
SubjectsHumans
RegulationUpregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold]
Odds Ratio/Hazard Ratio/Relative RiskNA
Effect on PathwaysPathways include (CCNB1): T cell receptor regulation of apoptosis, Cell cycle, Oncostatin M, Chk1/Chk2(Cds1)-mediated inactivation of cyclin B-Cdk1 complex, p53 signaling pathway
ExperimentTumor Vs Adjacent To Tumor
Type of BiomarkerDiagnostic
Cohort148 patients such as 23 were organ donors, 59 adjacent to Tumor, and 66 Tumor samples were included.
SenstivityNA
SpecificityNA
AUCNA
AccuracyValidation Set: 93.9%
Level Of Significancep=0.05
Method UsedImmunohistochemistry
ClinicalNo
RemarksUsing Prostate cancer as the training set, Liver samples were predicted with 97.7% accuracy, Lung cancer as 94.5% accuracy and Bladder cancer with 88.3% accuracy
Clinical Trial NumberNA
Degree Of ValidityValidated on independent patient dataset
Technical NameCCNB1: BUB1B: CLDN4: PCLAF: SLC39A6: SOX4: TOP2A: